Detalhe da pesquisa
1.
Correction: Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human antihuman VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C.
J Cell Sci
; 136(17)2023 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37675777
2.
Vascular endothelial growth factor receptor 3 directly regulates murine neurogenesis.
Genes Dev
; 25(8): 831-44, 2011 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21498572
3.
Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling.
Nature
; 484(7392): 110-4, 2012 Mar 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-22426001
4.
Pulmonary lymphangiectasia resulting from vascular endothelial growth factor-C overexpression during a critical period.
Circ Res
; 114(5): 806-22, 2014 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-24429550
5.
VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts.
EMBO J
; 29(8): 1377-88, 2010 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-20224550
6.
Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation.
Nature
; 454(7204): 656-60, 2008 Jul 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-18594512
7.
Xerna™ TME Panel is a machine learning-based transcriptomic biomarker designed to predict therapeutic response in multiple cancers.
Front Oncol
; 13: 1158345, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37251949
8.
Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models.
PLoS One
; 17(7): e0268244, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35849586
9.
Targeting lymphatic vessel activation and CCL21 production by vascular endothelial growth factor receptor-3 inhibition has novel immunomodulatory and antiarteriosclerotic effects in cardiac allografts.
Circulation
; 121(12): 1413-22, 2010 Mar 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-20231530
10.
Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity.
Nat Med
; 10(8): 813-5, 2004 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-15235599
11.
Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome.
Proc Natl Acad Sci U S A
; 105(47): 18513-8, 2008 Nov 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-19017793
12.
Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth.
Cancer Res
; 67(2): 593-9, 2007 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17234768
13.
Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy.
Oncotarget
; 10(53): 5523-5533, 2019 Sep 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31565186
14.
Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation.
J Clin Invest
; 115(2): 247-57, 2005 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-15668734
15.
Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis.
FASEB J
; 21(4): 1003-12, 2007 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-17210781
16.
Blockade of VEGFR3-signalling specifically inhibits lymphangiogenesis in inflammatory corneal neovascularisation.
Graefes Arch Clin Exp Ophthalmol
; 246(1): 115-9, 2008 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-17909835
17.
Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2.
Cancer Res
; 66(5): 2650-7, 2006 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16510584
18.
VEGF-C promotes the development of lymphatics in bone and bone loss.
Elife
; 72018 04 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29620526
19.
Blockade of Vascular Endothelial Growth Factor Receptor-1 (Flt-1), Reveals a Novel Analgesic For Osteoarthritis-Induced Joint Pain.
Gene Rep
; 11: 94-100, 2018 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30873504
20.
Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factor-a/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells.
Cancer Res
; 65(8): 3185-92, 2005 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15833849